Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQEJVU)

Drug Name

1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Drug Info

Synonyms

1-((2-Chlorophenyl)diphenylmethyl)-1H-pyrazole; TRAM-34; 289905-88-0; Tram 34; 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole; AC1LCVHZ; CHEMBL498270; CHEBI:34990; 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole; 1-(2-Chlorophenyl)diphenyl)methyl]-1H-pyrazole; SureCN41130; TRAM34; SCHEMBL41130; GTPL2336; KS-00000OJW; CTK0J1643; DTXSID70349650; MolPort-003-850-592; EX-A2316; BCP01324; ZINC3975392; BDBM50279107; ANW-72309; s1160; MFCD09842562; AKOS005146304; CS-1921; ACN-048484; MP-2041; API0000868; DS-2617; NCGC00165909-03; NCGC00165909-02

Indication

Disease Entry	ICD 11	Status	REF
Conjunctival fibrosis	9A61.3	Investigative	[1]

Cross-matching ID

PubChem CID: 656734
ChEBI ID: CHEBI:34990
CAS Number: CAS 289905-88-0
TTD Drug ID: DMQEJVU

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Calcium-activated potassium channel (KCN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[5]
Charybdotoxin	DMKN345	Scorpion envenoming syndrome	8D43	Approved	[6]
ICA-17043	DMRFY7I	Alzheimer disease	8A20	Phase 2	[7]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	DMKMH5L	Discovery agent	N.A.	Investigative	[2]
4-fluorophenyl-2,2-diphenylacetamide	DMI03KV	Discovery agent	N.A.	Investigative	[7]
N-methyl-2,2,2-triphenylacetamide	DMQGRMO	Discovery agent	N.A.	Investigative	[7]
TRIPHENYLMETHANAMINE	DM3CQIZ	Discovery agent	N.A.	Investigative	[7]
N,N-dimethyl-2,2,2-triphenylacetamide	DM9XZJN	Discovery agent	N.A.	Investigative	[7]
(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide	DMFV76H	Discovery agent	N.A.	Investigative	[7]
2,2,2-tris-(3-fluorophenyl)-acetamide	DMJXAF7	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Calcium-activated potassium channel KCa3.1 (KCNN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ICA-17043	DMRFY7I	Alzheimer disease	8A20	Phase 2	[8]
ASP0819	DM6HJ3V	Fibromyalgia	MG30.01	Phase 2	[9]
EBIO	DMPKI0N	Discovery agent	N.A.	Investigative	[10]
DC-EBIO	DM2T5OV	Discovery agent	N.A.	Investigative	[11]
SKA-121	DMBL7YN	Discovery agent	N.A.	Investigative	[12]
PMID15603962Crac-16	DMN5LZQ	Discovery agent	N.A.	Investigative	[13]
SKA-31	DMX34F1	Discovery agent	N.A.	Investigative	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Drug(s) Affected By Estrogen receptor (ESR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[15]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[16]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[17]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[18]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[19]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[20]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[21]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[18]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[23]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[24]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[27]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[28]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[29]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[30]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[31]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[32]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-activated potassium channel (KCN)	TTMNI76	NOUNIPROTAC	Inhibitor	[2]
Calcium-activated potassium channel KCa3.1 (KCNN4)	TT7M9I6	KCNN4_HUMAN	Blocker (channel blocker)	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Gene/Protein Processing	[4]
Progesterone receptor (PGR)	OT0FZ3QE	PRGR_HUMAN	Gene/Protein Processing	[4]

------------------------------------------------------------------------------------

References

1	Blockade of KCa3.1: A novel target to treat TGF-1 induced conjunctival fibrosis.Exp Eye Res. 2018 Feb;167:140-144.
2	Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
3	Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.
4	The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. doi: 10.1111/j.1476-5381.2009.00557.x. Epub 2009 Dec 24.
5	Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
6	Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
7	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
8	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9.
9	Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369.
10	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
11	Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2001 Feb;296(2):600-11.
12	New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol. 2014 Sep;86(3):342-57.
13	IKCa-channel blockers. Part 2: discovery of cyclohexadienes. Bioorg Med Chem Lett. 2005 Jan 17;15(2):401-4.
14	Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009 Feb;75(2):281-95.
15	Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
16	Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
17	Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
18	Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
19	The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
20	Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
21	Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
22	Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
23	Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
24	Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
25	Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov;68(10-13):891-905. doi: 10.1016/j.steroids.2003.08.008.
26	Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. Int J Oncol. 2000 Nov;17(5):991-1000. doi: 10.3892/ijo.17.5.991.
27	Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene. 2005 Jun 23;24(27):4388-400. doi: 10.1038/sj.onc.1208623.
28	Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects. Steroids. 2005 Nov;70(12):840-5. doi: 10.1016/j.steroids.2005.04.010.
29	Expression of estrogen-, progesterone-, and androgen-responsive genes in MCF-7 and MDA-MB-231 cells treated with o,p'-DDT, p,p'-DDT, or endosulfan. J Biochem Mol Toxicol. 2021 Jun;35(6):1-8. doi: 10.1002/jbt.22773. Epub 2021 Mar 16.
30	Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. Breast Cancer Res Treat. 2009 Aug;116(3):461-70. doi: 10.1007/s10549-008-0151-x. Epub 2008 Aug 3.
31	A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):94-103. doi: 10.1016/j.ejogrb.2006.07.042. Epub 2006 Sep 14.
32	Serum free BG-1 cell proliferation assay: a sensitive method for determining organochlorine pesticide estrogen receptor activation at the nanomolar range. Toxicol In Vitro. 2006 Apr;20(3):382-94. doi: 10.1016/j.tiv.2005.08.016. Epub 2005 Oct 19.
33	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.